Bruns Tony, Reuken Philipp A, Stengel Sven, Gerber Ludmila, Appenrodt Beate, Schade Johannes H, Lammert Frank, Zeuzem Stefan, Stallmach Andreas
The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany.
Department of Internal Medicine IV (Gastroenterology, Hepatology, and Infectious Diseases), Jena University Hospital, Jena, Germany.
Liver Int. 2016 Aug;36(8):1133-42. doi: 10.1111/liv.13095. Epub 2016 Mar 23.
BACKGROUND & AIMS: Circulating and peritoneal fragments of microbial DNA (bactDNA) are evidence for bacterial translocation in decompensated cirrhosis and may serve as a rational approach for antibiotic therapy when infection is suspected.
Prospective multicenter study to investigate whether identification of bactDNA from blood or ascitic fluid (AF) by multiplex polymerase chain reaction (PCR) is associated with increased 90-day mortality in 218 patients with cirrhosis and signs of infection.
BactDNA in either compartment was detected in 134 (61%) patients, comprising 54 with bactDNA in blood and AF, 48 with AF bactDNA only, and 32 with blood bactDNA only. BactDNA was associated with spontaneous bacterial peritonitis and blood stream infections (SBP/BSI), acute-on-chronic liver failure (ACLF), encephalopathy and markers of inflammation. The prevalence of bactDNA in patients with proven SBP/BSI (36/49; 73%) was similar to that in patients with sterile ACLF (37/52; 71%). Actuarial 90-day survival was 56 ± 5% in the absence of bactDNA in both compartments and did not differ if bactDNA was detected in blood only (63 ± 9%), AF only (63 ± 7%), or in blood and AF (52 ± 7%). Predictors of 90-day mortality were SBP (HR = 3.10; 95% CI: 1.90-5.06), BSI (HR = 4.94; 95% CI: 2.71-9.02), and ACLF (HR = 2.20; 95% CI: 1.44-3.35). The detection of resistance genes in blood or AF in the absence of SBP/BSI (n = 11) was associated with poor 1-year survival (HR = 2.35; 95% CI: 1.03-5.35).
BactDNA in sterile body fluids did not indicate increased mortality in cirrhotic patients with suspected infection. Using multiplex PCR for risk stratification cannot be recommended in these patients.
微生物DNA(细菌DNA)的循环片段和腹膜片段是失代偿期肝硬化患者细菌移位的证据,在怀疑感染时可作为抗生素治疗的合理依据。
一项前瞻性多中心研究,旨在调查通过多重聚合酶链反应(PCR)从血液或腹水(AF)中鉴定细菌DNA是否与218例有感染迹象的肝硬化患者90天死亡率增加相关。
134例(61%)患者的任一部位检测到细菌DNA,其中54例血液和腹水中均有细菌DNA,48例仅腹水中有细菌DNA,32例仅血液中有细菌DNA。细菌DNA与自发性细菌性腹膜炎和血流感染(SBP/BSI)、慢加急性肝衰竭(ACLF)、肝性脑病及炎症标志物相关。确诊SBP/BSI患者(36/49;73%)中细菌DNA的患病率与无菌性ACLF患者(37/52;71%)相似。两个部位均未检测到细菌DNA时,90天精算生存率为56±5%,仅血液中检测到细菌DNA(63±9%)、仅腹水中检测到细菌DNA(63±7%)或血液和腹水中均检测到细菌DNA(52±7%)时,生存率无差异。90天死亡率的预测因素为SBP(HR = 3.10;95%CI:1.90 - 5.06)、BSI(HR = 4.94;95%CI:2.71 - 9.02)和ACLF(HR = 2.20;95%CI:1.44 - 3.35)。在无SBP/BSI情况下(n = 11)血液或腹水中检测到耐药基因与1年生存率低相关(HR = 2.35;95%CI:1.03 - 5.35)。
无菌体液中的细菌DNA并未提示疑似感染的肝硬化患者死亡率增加。不推荐在这些患者中使用多重PCR进行风险分层。